Application of proteomics in study of hepatocellular carcinoma
-
摘要: 肝细胞癌(HCC)是世界上病死率最高的恶性肿瘤之一。蛋白质组学是前沿研究领域重要组成部分,被广泛应用于有关疾病的研究中,是目前HCC研究的重要方法。显著表达的蛋白可以被筛选出来,有望成为HCC早期诊断生物标志物、药物作用靶点以及用来预测HCC复发和预后、阐明HCC致病机制。概述了国内外对于HCC蛋白质组学在临床研究中的成果,认为蛋白质组学技术基础研究成果的临床转化,将会为HCC诊疗带来极大益处。Abstract: Hepatocellular carcinoma ( HCC) is one of the most fatal malignant tumors worldwide. As an important part of cutting- edge research fields, proteomics has been widely used in the studies of related diseases and has currently become a crucial experimental approach to research on HCC. Significantly expressed proteins can be identified as potential biomarkers for early diagnosis and targets for therapeutic drugs for HCC. Moreover, they can be used for prediction of the recurrence and prognosis of HCC, as well as for investigation of pathogenesis of the disease. The proteomic results from worldwide clinical studies of HCC are summarized, and it is suggested that the clinical application of results of basic research on HCC proteomics will bring great benefit to the diagnosis and treatment of HCC.
-
Key words:
- carcinoma, hepatocellular /
- proteomics /
- biomarkers, pharmacological /
- review
-
[1] EL-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:Epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576. [2]World Health Organization Mortality Database.WHO Statistical Information System[EB/OL].[2014-01-07].http://www.who.int/whosis/en/. [3]KASSAHUN WT, FANGMANN J, HARMS J, et al.Liver resection and transplantation in the management of hepatocellular carcinoma:a review[J].Exp Clin Transplant, 2006, 4 (2) :549-558. [4] ARRELL DK, NEVEROVA I, van EYK JE.Cardiovascular proteomics:evolution and potential[J].Circ Res, 2001, 88 (8) :763-773. [5] WIERZBA K, MUROI M, OSADA H.Proteomics accelerating the identification of the target molecule of bioactive small molecules[J].Curr Opin Chem Biol, 2011, 15 (1) :57-65. [6]RIFAI N, GILLETTE MA, CART SA.Protein biomarker discovery and validation:the long and uncertain path to clinical utility[J].Nat Biotechnol, 2006, 24 (8) :971-983. [7]KANG XN, SUN L, GUO K, et al.Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS[J].J Cancer Res Clin Oncol, 2010, 136 (8) :1151-1159. [8]JIN GZ, DONG H, YU WL, et al.A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values[J].BMC Cancer, 2013, 13:161. [9]TSAI ST, TSOU CC, MAO WY, et al.Label-free quantitative proteomics of CD133-positive liver cancer stem cells[J].Proteome Sci, 2012, 10 (1) :69. [10] YEO M, NA YM, KIM DK, et al.The loss of phenol sulfotransferase-1 in hepatocellular carcinogenesis[J].Proteomics, 2010, 10 (2) :266-276. [11]SUN S, POON RT, LEE NP, et al.Proteomics of hepatocellular carcinoma:serum vimentin as a surrogate marker for small tumors (≤2 cm) [J].J Proteome Res, 2010, 9 (4) :1923-1930. [12]LI N, LONG Y, FAN X, et al.Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues[J].J Exp Clin Cancer Res, 2009, 28:122. [13]KANMURA S, UTO H, SATO Y, et al.The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma[J].J Gastroenterol, 2010, 45 (4) :459-467. [14]WANG X, CHEN Y, HAN QB, et al.Proteomic identification of molecular targets of gambogic acid:role of stathmin in hepatocellular carcinoma[J].Proteomics, 2009, 9 (2) :242-253. [15]GOU L, WANG W, TONG A, et al.Proteomic identification of RhoA as a potential biomarker for proliferation and metastasis in hepatocellular carcinoma[J].J Mol Med (Berl) , 2011, 89 (8) :817-827. [16]REN F, WU H, LEI Y, et al.Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma[J].Mol Cancer, 2010, 9:81. [17]HU MY, LAM CT, LIU KD.Proteomic identification of a monoclonal antibody recognizing caveolin-l in hepatocellular carcinoma with metastatic potential[J].Protein Pept Lett, 2009, 16 (5) :479-485. [18]LIU H, FU X, JI W, et al.Human sulfatase-1 inhibits the migration and proliferation of SMMC-7721 hepatocellular carcinoma cells by downregulating the growth factor signaling[J].Hepatol Res, 2013, 43 (5) :516-525. [19]WU L, PENG CW, HOU JX, et al.Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation[J].J Exp Clin Cancer Res, 2010, 29:17. [20]LI Y, WUJ, ZHANGW, et al.Identificationof serumCCL15inhepatocellular carcinoma[J].Br J Cancer, 2013, 108 (1) :99-106. [21]ZHAO P, ZHANG W, WANG SJ, et al.HAb18G/CD147 promotes cell motility by regulating annexin ii-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells[J].Hepatology, 2011, 54 (6) :2012-2024. [22]YOKOO H, KONDO T, OKANO T, et al.Protein expression associated with early intrahepatic recurrence of hepatoeellular carcinoma after curative surgery[J].Cancer Sci, 2007, 98 (5) :665-673.引证本文:WANG JG, FEI XY, SONG Q.Application of proteomics in study of hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (9) :958-960. (in Chinese) 王建钢, 费新应, 宋青.蛋白质组学研究技术在肝细胞癌诊疗中的应用[J].临床肝胆病杂志, 2014, 30 (9) :958-960.
本文二维码
计量
- 文章访问数: 2652
- HTML全文浏览量: 24
- PDF下载量: 533
- 被引次数: 0